🇺🇸 FDA

Company profile · Sponsor

Celgene

Celgene Europe Limited

EA7D4EE · EMA pharma GB
Pipeline
24
Drugs
0
Patents
0

Quick answer

Celgene (EA7D4EE) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EA7D4EE
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (24)

Search pipeline →

  1. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  2. BENDAMUSTINE HYDROCHLORIDE, PREDNISOLONE , CYCLOPHOSPHAMIDE, LENALIDOMIDE, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, Golcadomide, Golcadomide, PEGFILGRASTIM, Golcadomide, BENDAMUSTINE HYDROCHLORIDE, RITUXIMAB, LENALIDOMIDE, RITUXIMAB, VINCRISTINE SULFATE, LENALIDOMIDE, LENALIDOMIDE, CYCLOPHOSPHAMIDE, Golcadomide, DOXORUBICIN HYDROCHLORIDE

    Celgene

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  3. CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, POMALIDOMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE, CYCLOPHOSPHAMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, POMALIDOMIDE, DARATUMUMAB, GPRC5D-TARGETED CAR T, DEXAMETHASONE SODIUM PHOSPHATE, POMALIDOMIDE, TOCILIZUMAB

    Celgene

    Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. Cendakimab

    Celgene

    Eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  5. DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -

    Celgene

    Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis

    phase 3 small molecule active

    1 trial

  6. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  7. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , BORTEZOMIB, DARZALEX 1800 mg solution for injection, Dexamethason-ratiopharm® 4 mg Tabletten, Iberdomide, Iberdomide

    Celgene

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  9. Imnovid 1 mg hard capsules, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, Imnovid 4 mg hard capsules, Dexamethason CF 20 mg/ml, injectievloeistof, CC-92480, Dexamethason 4 mg JENAPHARM®, Imnovid 2 mg hard capsules, DEXAMETHASONE, Dexamethason 4 mg GALEN®, CC-92480, Imnovid 3 mg hard capsules, CC-92480, CC-92480, VELCADE 1 mg powder for solution for injection

    Celgene

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  10. Ozanimod, Ozanimod

    Celgene

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  11. Ozanimod, Ozanimod

    Celgene

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  12. PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE

    Celgene

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  13. Placebo matching Ozanimod hard-gelatin capsules, Ozanimod, Ozanimod

    Celgene

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  14. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene

    Myelodysplastic syndrome

    phase 3 small molecule active

    1 trial

  15. Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection

    Celgene

    myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  16. VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE

    Celgene

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.92 mg hard capsules

    Celgene

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  18. Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg

    Celgene

    Relapsed and/or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. Azacitidine 150mg tablet, Azacitidine 200mg tablet: film- coated tablet, azacitidine, PEMBROLIZUMAB, azacitidine

    Celgene

    Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. CC-92480, Dexamethason acis 8 mg Tabletten, Dexamethason 8 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason 4 mg JENAPHARM®, Dexamethason-ratiopharm® 4 mg Tabletten

    Celgene

    Relapsed and refractory multiple myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  21. CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg

    Celgene

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  22. CD19-Targeted NEX-T CAR T, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, CYCLOPHOSPHAMIDE

    Celgene

    Lupus Nephritis, Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  23. CYCLOPHOSPHAMIDE, PREDNISOLONE , Golcadomide, VINCRISTINE SULFATE, PEGFILGRASTIM, RITUXIMAB, Golcadomide, DOXORUBICIN, Golcadomide, VINCRISTINE SULFATE, RITUXIMAB, Golcadomide, PREDNISONE, BENDAMUSTINE HYDROCHLORIDE

    Celgene

    Newly Diagnosed Advanced Stage Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  24. DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Empliciti 400 mg powder for concentrate for solution for infusion., Dexamethason CF 20 mg/ml, injectievloeistof, Dexamethasone 2mg Tablets, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Dexamethason 4 mg JENAPHARM®, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, CC-92480, CC-92480

    Celgene

    Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Celgene?

Celgene (EA7D4EE) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Celgene sponsor?

We track 24 ClinicalTrials.gov-linked programs for Celgene, including 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Celgene company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.